Liquidia (LQDA) Net Income towards Common Stockholders Growth (3y) (2023 - 2026)
Powered by 
Analysis
Liquidia (LQDA) Net Income towards Common Stockholders Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.53 Bn | 625.77 Bn | 17.26 Bn | 2.47% |
| 2 | AbbVie | 442.27 Bn | 435.70 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 366.81 Bn | 359.67 Bn | 12.21 Bn | 39.28% |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | 12.12% |
| 5 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn | -28.09% |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | -36.57% |
| 7 | Revolution Medicines | 44.12 Bn | 44.12 Bn | - | - |
| 8 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn | 42.23% |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn | 8.71% |
| 10 | Liquidia | 6.09 Bn | 5.80 Bn | 160.92 Mn | 72.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 72.98% |
| Mar 31, 2026 | 96.64% |
| Dec 31, 2025 | 61.70% |
| Sep 30, 2025 | 27.03% |
| Jun 30, 2025 | -63.88% |
| Mar 31, 2025 | -36.92% |
| Dec 31, 2024 | -49.34% |
| Sep 30, 2024 | -62.13% |
| Jun 30, 2024 | -63.56% |
| Mar 31, 2024 | -48.80% |
| Dec 31, 2023 | -19.50% |
| Sep 30, 2023 | -1.80% |
| Jun 30, 2023 | -19.11% |
| Mar 31, 2023 | 13.92% |